pharmaphorum

OCTOBER 13, 2020

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. The company has considerably more cash than at the start of the year – on 31 July it had £15.1

Gene Silencing 100

Gene Silencing Gene RNA Genome 100

pharmaphorum

DECEMBER 23, 2020

Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. In summer, Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder Oxlumo was approved in the European Union and the US.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

Delveinsight

AUGUST 6, 2020

The present hATTR treatment market constitutes compounds that stabilize the TTR tetramers, a TTR-directed small interfering RNA, and a TTR-directed antisense oligonucleotide, along with supportive therapies. Gene-silencing Therapies. hATTR market : In The Pipeline.

Protein 52

Protein Gene Silencing Marketing Gene 52